Eckert & Ziegler: Large-Scale Contracts for MultiSource Radiation Systems

Berlin, (PresseBox) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist in cancer diagnostic and treatment products, has increased its role as a provider of radiation therapy products in the Commonwealth of Independent States (CIS) via the acquisition of several large-scale contracts. Commissioned by the Kazakh, Ukrainian, and Russian governments as well as by the International Atomic Energy Agency, headquartered in Vienna, Eckert & Ziegler's Berlin-based subsidiary BEBIG GmbH will be supplying a dozen cancer clinics in Kazakhstan, the Ukraine, Russia, and Armenia with the "MultiSource" tumor radiation systems before the end of this year. The contracts have a total volume of well over 2 million EUR.

Dr. Edgar Löffler, Eckert & Ziegler AG's Executive Board member in charge of the therapy segment explains that "the installation of these systems offers significant support for the fight against cancer in these regions. The installations will additionally strengthen our market position in the CIS, where the introduction of our innovative, cost-saving radiation sources has been very well received, not only by specialists in the field, but also by the international organizations that subsidize such systems. We therefore anticipate that our "MultiSource" high dose radiation system (HDR) will continue to be highly esteemed by its buyers and users."

HDR brachytherapy is a minimally invasive patient friendly, ambulant radiation procedure whereby a miniature radiation source is placed inside the body in very close proximity of the tumor. This reduces unnecessary patient radiation exposure and leads to better treatment results.

About Eckert & Ziegler BEBIG GmbH Eckert & Ziegler BEBIG GmbH has been manufacturing radiation therapy products for more than sixteen years, and has in many countries acquired a leading market position for tumor radiation systems. The company is also Europe's leading producer of implants for the treatment of prostate cancer.

Eckert & Ziegler AG is an internationally active specialist for radioactive applications in medicine, science, and industry. Listed on the Frankfurt Prime Standard, the company posted sales of 54 million EUR in 2007, and currently has approximately 430 employees.

Eckert & Ziegler Strahlen- und Medizintechnik AG

For over forty (40) years, Eckert & Ziegler Isotope Products, (a subsidiary of Eckert & Ziegler AG) has been producing instrumentation and calibration standards. Today it is the world's leading manufacturer for nuclear imaging reference and calibration standards and a leading producer of radioactive components for industrial, scientific and medical applications.

Eckert & Ziegler AG is a global isotope technology company that processes radioisotopes as well as develops, manufactures and sells isotope technology components, medical technology equipment and related products.

Eckert & Ziegler employs over 430 people worldwide. Throughout all of its subsidiaries it generates yearly consolidated revenues in excess of $ 83 MM(54 Mio. EUR). Eckert & Ziegler AG is listed in the Prime Standard of the German Stock Exchange in Frankfurt am Main (ISIN DE0005659700).

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

Welche Jobs wird die Künstliche Intelligenz zuerst übernehmen?

Der Ein­satz von Künst­li­cher In­tel­li­genz (KI) bie­tet für Un­ter­neh­men gro­ße Chan­cen – stei­gen­de Um­sät­ze und neue Ar­beits­s­tel­len. Doch der ver­stärk­te Fo­kus auf die smar­te Tech­no­lo­gie könn­te lang­fris­tig auch vie­le Men­schen vom Ar­beits­markt ver­drän­gen.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.